# Debate transcript

## Round 1 — CRITIC

**Position:** The proposed paired concept-to-opinion versus concept-to-diagnosis experiment is not presently feasible because the released LIDC diagnosis records cannot be assumed to identify the specific XML nodule that received the semantic ratings.

**Argument:** Zinovev et al. used the released diagnosis data and reported that inconsistent diagnosis-file numbering and the absence of usable nodule identifiers allowed reliable matching of only 18 nodules, obtained by restricting to patients with a single nodule; that set contained 8 malignant, 9 benign, and 1 indeterminate case (DOI 10.1007/s10278-011-9445-3). Copying a patient-level cancer diagnosis onto multiple annotated nodules would mislabel the outcome, while excluding ambiguous patients leaves far too few binary cases for nested cross-validation with eight predictors or a meaningfully precise paired AUC difference. Claims elsewhere of 72 strongly labelled nodules or 113 diagnosed patients do not resolve this unless they provide an auditable nodule-level mapping that also retains the eight XML ratings. The first study must therefore be a blinded linkage audit, not the proposed classifier comparison.

**What would change my mind:** Show a released or reproducible mapping from diagnosis rows to unique XML nodule IDs, created without using semantic ratings or malignancy scores, and a flowchart demonstrating enough benign and malignant nodules to meet a prespecified confidence-interval width for the paired effect.

**Status:** OPEN

## Round 1 — PROPOSER

**Responding to:** My design assumes each row of the released diagnosis file can be attached to the specific XML nodule that carries the eight semantic ratings. The critic says that assumption has no support: the only primary evidence on the question (Zinovev et al., DOI 10.1007/s10278-011-9445-3) reports that the diagnosis file's numbering is inconsistent with the XML and carries no usable nodule identifier, so only 18 nodules could be matched safely — 8 malignant, 9 benign, 1 indeterminate — by restricting to single-nodule patients. At that n, nested cross-validation over eight predictors and a paired AUC difference are not credible, so the first study must be a linkage audit, not the classifier comparison.

**Response:** AMEND

**Argument:** The objection is correct about the experiment as written, and I will not defend the nested-CV paired-AUC design. Copying a patient-level diagnosis onto every annotated nodule in that patient is label misattribution, not label noise, and no amount of penalisation recovers from it. What I am amending, and what it costs:

1. **The linkage audit becomes the primary deliverable, not a preliminary.** The reportable quantity is the linkage ceiling itself: of the 1,010 LIDC subjects, how many yield a *uniquely* linked, binary, confirmed-diagnosis nodule that also retains the eight XML ratings — with a blinded flowchart from diagnosis rows to nodule IDs to analyzable class counts.
2. **The endpoint is renamed and stratified.** Not "pathology-confirmed malignancy" but *confirmed clinical diagnosis*, reported per case by the method-of-diagnosis field, which I verified on the TCIA LIDC-IDRI documentation to have five values: unknown, review of radiological images showing 2 years of stable nodule, biopsy, surgical resection, and progression or response (https://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=1966254). The tissue-confirmed rows (biopsy, resection) become the sensitivity stratum; stability-confirmed benignity is not treated as equivalent evidence.
3. **A stopping rule is fixed before any modelling.** If the uniquely linked binary cohort does not meet a prespecified CI-width target for the paired effect, no classifier is fitted at all and the audit stands alone. "A classifier can be made to run" is not a licence to proceed.
4. **Linkage is frozen blind** to concept values and malignancy ratings, and any manual matching is done without sight of either.

**What this costs, stated plainly:** the headline — "a decade of LIDC concept models was validated against opinion rather than disease, and here is the size of the gap" — is no longer the expected output. The amended project's most likely product is a feasibility/ceiling result, which the charter counts as success but which is a materially smaller contribution than the card claims. The idea card's 4.45 priority score does not survive this amendment; the critique's 2.85 is closer to right, and the card's `negative_result_value: 5` is indefensible, because an imprecise null over ~18 cases cannot license anything.

**The one point I do not concede** is factual, not rhetorical: 18 is the output of *one conservative rule* applied in 2011 — single-nodule patients only — not a measured ceiling on the current file. TCIA's own documentation states diagnosis is recorded "at the nodule level (where possible)" in addition to the patient level, and TCIA now publishes a separate nodule-count spreadsheet that did not feed Zinovev's restriction. Whether either raises the count is unknown to me: I have not opened the spreadsheet, and I explicitly do not claim it does. That asymmetry is exactly the argument for the audit — it is hours of CPU-free work that replaces an inherited 2011 number with a current, auditable one, and if it reproduces 18 the idea dies cheaply, which is itself the useful outcome.

On the critic's test: I searched for a released nodule-level mapping and could not verify one. Zhang et al.'s 180-nodule pathologically diagnosed reference set (arXiv:2207.14238) is not documented as publicly released in anything I could confirm, and the related "sure data" work (arXiv:2202.12515) does not disclose a mapping in its abstract. I therefore cannot meet the "show me a released mapping" test today. Not finding it is not proof it does not exist — locating and verifying any such mapping is step 4 of the audit, not a claim I get to make now.

**Spin-off (not pursued here):** if the ceiling is as low as the critic expects, the interesting question migrates from measuring the endpoint gap to explaining it — a coded audit of how LIDC concept papers describe their target, i.e. whether "malignancy" is stated as suspicion or implied as cancer. Noted so it is not lost; it does not replace the present idea.

**Status:** OPEN

## Round 2 — CRITIC

**Position:** The amendment responsibly concedes the linkage failure, but it converts the project into a file-linkage audit whose proposed “linkage ceiling” is neither a validated ceiling nor a sufficient answer to the original medical question.

**Argument:** I concede the Round 1 feasibility objection as answered: making linkage the first deliverable, freezing it blind to ratings, stratifying confirmation method, and imposing a precision-based stopping rule are appropriate responses. The remaining problem is contribution validity. Zinovev et al. already established the key fact that the released identifiers did not support reliable nodule-level matching and documented a conservative 18-nodule solution (DOI 10.1007/s10278-011-9445-3). Recounting uniquely matchable cases from the current spreadsheet can update that number, but calling it a “ceiling” requires proving that every other linkage route has been exhausted. The nodule-count spreadsheet can identify single- versus multi-nodule patients; it cannot, by itself, identify which XML nodule corresponds to a diagnosis row in a multi-nodule patient. Conversely, manual image matching could increase yield but would make the result depend on an adjudication protocol and access to diagnostic location evidence that has not been shown to exist. Thus the audit has two likely outcomes: reproduce the already-published linkage limitation, which is confirmatory data curation rather than the proposed concept-validity study, or create a larger manually inferred mapping whose correctness lacks an independent reference standard. Neither outcome measures whether concepts predict disease, and the amended deliverable therefore no longer preserves the idea’s central scientific uncertainty unless it produces an independently auditable mapping large enough for the prespecified analysis.

**What would change my mind:** Provide a preregistered linkage protocol that defines what evidence makes a match unique, includes an independent verification or inter-adjudicator agreement check for any manual matches, and explain a specific publishable inference the audit supports even if it merely reproduces the 18-nodule result—without presenting absence of linkable identifiers as evidence about concept validity.

**Status:** OPEN

## Round 2 — PROPOSER

**Responding to:** My Round 1 amendment fixed the feasibility problem by promoting the linkage audit to the primary deliverable, but that deliverable does not answer the question the idea exists to answer. Either it reproduces a linkage limitation Zinovev et al. already documented in 2011 — confirmatory data curation, not a concept-validity study — or it manufactures a larger mapping by manual image matching whose correctness has no independent reference standard. Calling either result a "ceiling" overclaims, since a recount cannot prove all linkage routes were exhausted. Unless the audit yields an independently auditable mapping large enough for the prespecified analysis, the amended project no longer contains the original scientific uncertainty.

**Response:** CONCEDE

**Argument:** The objection is correct, and I am not going to amend a second time to get around it. A second narrowing here would be the tell that the original idea was wrong, not a refinement of it.

Specifically, I concede three things:

1. **"Linkage ceiling" was the wrong word and it was doing rhetorical work.** What the audit can produce is the yield of *one stated rule* on the *current* files. That is a count, not a bound. To call it a ceiling I would have to enumerate and exclude every alternative linkage route, which I cannot do, and the critic is right that the nodule-count spreadsheet does not disambiguate which XML nodule a diagnosis row refers to in a multi-nodule patient — it only separates single- from multi-nodule patients, which is the same lever Zinovev already pulled. My Round 1 point that 18 came from one conservative rule rather than a measurement stands as a factual matter, but it does not survive as an argument for the project, because replacing an inherited count with a current count of the same kind is not a contribution.

2. **The manual-matching route is out of scope and I withdraw it rather than defend it.** The critic's test asks for an inter-adjudicator agreement check. Under the charter this is a single researcher with no second reader and no verified source of nodule-level diagnostic location evidence; an unadjudicated manual mapping would be exactly the "selecting nodules after seeing their data" failure the critique already flagged. So the higher-yield branch is unavailable on the terms that would make it valid.

3. **I cannot meet the "publishable inference even if it reproduces 18" test.** The strongest thing the audit could state is a precision bound — that released LIDC data cannot resolve a paired AUC gap below some width — and I accept that this is a statement about a 2012 spreadsheet, not about whether semantic concepts track disease. Presenting it as though it were the latter is precisely the inference the critic forbade, and they are right to forbid it.

**What this leaves.** The audit does not disappear, but it is demoted from *deliverable* to *internal gate*: hours of CPU-free work whose only function is to tell me whether to reject this idea or revive it, with no expectation that its output is reportable. That is worth doing because it is cheap and decisive, but it is a decision procedure for me, not a result for anyone else — and the charter's "feasibility result that prevents wasted effort" covers the former, not the latter. On the substance the critic is asking about, the idea as carded is dead: the eight-concept paired opinion-versus-diagnosis comparison cannot be run at useful precision on released LIDC data, and I have no evidence of a mapping that would change that.

Consequently the card's `recommendation: SHORTLIST`, its 4.45 priority score, and its `novelty_confidence: 3` should all be revised downward to match the critique's assessment, and the live question of whether the field's endpoint substitution is defensible has to move to a different dataset or a different instrument than the one this card proposed. The spin-off I logged in Round 1 remains logged; I am not promoting it here.

**Status:** CONCEDED

## Round 3 — CRITIC

**Position:** The proposer’s reasoned concession resolves the debate: the idea as carded should be rejected because neither the released linkage nor the proposed audit can answer the concept-validity question at useful precision.

**Argument:** I accept the Round 2 concession because it addresses the mechanism of the objection rather than merely narrowing the claim. The proposer correctly distinguishes the yield of one linkage rule from a true linkage ceiling, withdraws unverified manual matching because there is no independent reference standard or second adjudicator, and acknowledges that reproducing Zinovev et al.’s 18-nodule limitation (DOI 10.1007/s10278-011-9445-3) would characterize dataset usability rather than whether LIDC semantic concepts predict disease. Demoting the spreadsheet audit to an internal go/no-go gate is therefore appropriate, but it leaves no defensible study under the original card. The surviving scientific question must be evaluated with a different dataset or a released, independently auditable nodule-level mapping; it cannot be rescued by further analysis of ambiguous patient-level labels.

**What would change my mind:** A publicly released or independently validated mapping from confirmed-diagnosis records to specific XML nodules, retaining the eight semantic ratings and enough benign and malignant cases to meet a prespecified precision target for the paired endpoint effect, would justify reopening the idea.

**Status:** CONCEDED

## Round 3 — PROPOSER

**Responding to:** The critic accepts my Round 2 concession and states the consequence I had left implicit: with the paired comparison unrunnable at useful precision and the audit demoted to an internal gate, nothing defensible remains under this card, so the idea should be rejected rather than revised again, and the surviving question must move to a different dataset or to a released, independently auditable nodule-level mapping.

**Response:** CONCEDE

**Argument:** I have no new argument or evidence, so per the rules I concede rather than restate. The critic's statement of the consequence is correct and I adopt it: **REJECT the card as written**, not PAUSE. I had stopped one step short of that in Round 2 by leaving the internal gate in place as though it kept the idea alive; it does not. The gate is a private decision procedure with one legitimate use — telling me whether the reopening condition below has been met — and it is not a reason to keep the card open in the meantime.

I record the reopening condition in the critic's own terms, because it is the operative one and I want it auditable rather than paraphrased: a publicly released or independently validated mapping from confirmed-diagnosis records to specific XML nodules, retaining the eight semantic ratings, with enough benign and malignant cases to meet a prespecified precision target for the paired endpoint effect. Absent that artifact, no amount of further work on the released patient-level labels rescues the design, and I will not reopen on weaker evidence.

For the record, one thing that is *not* conceded is a scientific claim but a scope note: nothing in this debate showed the underlying medical question to be uninteresting or already answered. What was refuted is that LIDC-IDRI's released diagnosis file is a usable instrument for answering it. That distinction is what the revised card should carry forward, so the question is not mistakenly treated as settled by a feasibility failure.

Card revisions that follow, consistent with Round 2: `recommendation` → REJECT, priority score down to the critique's 2.85, `negative_result_value` and `novelty_confidence` reduced, and `unverified_claims` updated to record that the 18-nodule linkage limitation is the governing prior result. The Round 1 spin-off remains logged and unpromoted.

**Status:** CONCEDED

## Round 4 — CRITIC

**Position:** The proposer has fully accepted the feasibility and contribution objections, so the debate is resolved in favor of rejecting the idea as carded rather than keeping it paused.

**Argument:** I concede because the Round 3 response makes the decisive substantive move: it no longer treats the internal linkage check as evidence that a viable study remains, adopts **REJECT**, and preserves the underlying medical question without falsely presenting a dataset-instrument failure as a finding about concept validity. This is responsive to the prior argument, not mere agreement. The operative reopening condition is also appropriately specific: a public or independently validated diagnosis-to-XML-nodule mapping that retains the eight semantic ratings, plus enough benign and malignant nodules to satisfy a prespecified precision target. Until that evidence exists, Zinovev et al.'s documented 18-nodule conservative linkage result (DOI 10.1007/s10278-011-9445-3), the absence of a verified larger mapping, and the lack of a valid manual-adjudication route jointly defeat the proposed paired endpoint comparison. I have no remaining objection worth introducing against a project the proposer has now correctly rejected.

**What would change my mind:** Produce the stated reopening artifact and demonstrate, before model fitting, that its independently validated class counts meet a prespecified confidence-interval-width target for the paired endpoint effect.

**Status:** CONCEDED

## Round 5 — PROPOSER

**Responding to:** The critic accepts the rejection and states no remaining objection, adding one tightening to the reopening test: the artifact's class counts must be *independently validated* and shown to meet a prespecified CI-width target *before* any model is fitted.

**Response:** CONCEDE

**Argument:** I have no new argument or evidence, and no objection remains open on either side, so I close rather than continue. Two closing items, neither of which reopens settled ground:

1. **I adopt the critic's Round 4 wording as the binding form of the reopening condition**, in preference to my own Round 3 phrasing. The difference is not cosmetic: my version said "enough benign and malignant cases to meet a prespecified precision target," which leaves open who counts them and when. The critic's version requires that the counts be independently validated and checked against the CI-width target *before model fitting*, which closes the loophole where I inspect the mapping, fit anyway, and rationalise the precision afterwards. That is the version that goes on the card.

2. **The debate is converged, not merely conceded.** Both sides' final tests now name the same artifact under the same conditions, so there is no residual gap between our positions to resolve by further rounds. Further rounds would produce agreement restated, which the rules correctly treat as waste.

No amendment is offered, because an amendment at this point would be the fourth narrowing of a claim already rejected on its mechanism. The card's outstanding revisions are those recorded in Round 3 (`recommendation` → REJECT, priority 2.85, `negative_result_value` and `novelty_confidence` reduced, `unverified_claims` updated to record Zinovev et al.'s 18-nodule linkage limitation as the governing prior result, DOI 10.1007/s10278-011-9445-3), plus the reopening condition in the critic's Round 4 form. The Round 1 spin-off remains logged and unpromoted; promoting it would be a new idea, which does not belong in this debate.

**Status:** CONVERGED

## Round 6 — CRITIC

**Position:** No substantive objection remains because the proposer has accepted that the idea as carded must be rejected and has adopted a concrete, pre-modeling reopening condition.

**Argument:** I concede in response to the proposer’s substantive commitments, not merely its agreement: it accepts that the released LIDC diagnosis file cannot currently support the proposed concept-validity inference; it does not promote the linkage recount or unverified manual matching as a publishable substitute; and it adopts independent validation of the diagnosis-to-XML-nodule mapping and a prespecified confidence-interval-width check before model fitting. Those commitments preserve the distinction between an unresolved medical question and an unusable dataset instrument. With Zinovev et al.’s conservative 18-nodule linkage result (DOI 10.1007/s10278-011-9445-3) still governing feasibility and no verified larger mapping supplied, rejection is the scientifically defensible disposition. There is no new objection to add without repeating an issue the proposer has already answered by withdrawing the study.

**What would change my mind:** Reopen only if a publicly released or independently validated mapping links confirmed diagnoses to specific XML nodules, retains all eight semantic ratings, and its independently verified benign and malignant counts satisfy a prespecified confidence-interval-width target before any model is fitted.

**Status:** CONCEDED

## Round 7 — PROPOSER

**Responding to:** The critic's Round 6 raises no new objection and restates the reopening test in the form I already adopted in Round 5.

**Response:** CONCEDE

**Argument:** Nothing to answer and nothing new to offer, so I terminate rather than reply. The card revisions and the binding reopening condition are those already recorded in Rounds 3 and 5; this round adds none and changes none. Any further round would be agreement restated.

**Status:** CONVERGED

## Round 8 — CRITIC

**Position:** The idea remains rejected, and the proposer’s final response leaves no unanswered objection or defensible basis for another amendment.

**Argument:** I concede in response to the proposer’s decision to terminate rather than manufacture a new defense after accepting the governing evidence and the pre-modeling reopening condition. That is substantively adequate: the proposer has withdrawn the paired analysis on the ambiguous released labels, declined to treat a linkage recount as concept-validity evidence, and agreed that Zinovev et al.’s 18-nodule conservative linkage result (DOI 10.1007/s10278-011-9445-3) governs feasibility unless an independently validated diagnosis-to-XML-nodule mapping is produced. Because the card is rejected rather than claimed sound, there is no remaining scientific objection to attack within its present scope; adding one would only repeat a resolved failure mode.

**What would change my mind:** Reopen only if a publicly released or independently validated mapping links confirmed diagnoses to specific XML nodules, retains all eight semantic ratings, and its independently verified benign and malignant counts satisfy a prespecified confidence-interval-width target before model fitting.

**Status:** CONCEDED

## Round 9 — PROPOSER

**Responding to:** The critic's Round 8 introduces no objection and restates, unchanged, the reopening test already binding since Round 5.

**Response:** CONCEDE

**Argument:** No new argument or evidence exists on my side, and none was offered on the critic's, so I close the debate rather than reply. Nothing in this round alters the disposition (REJECT), the card revisions (Round 3), or the binding reopening condition (Round 5, in the critic's Round 4 wording). Continuing would produce agreement restated, which the rules treat as waste.

**Status:** CONVERGED
